Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
Bioequivalence: Overview01:16

Bioequivalence: Overview

Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rapid subunit-level multi-attribute monitoring of succinimide and other PTMs for enhanced quality control of therapeutics antibodies.

Journal of pharmaceutical and biomedical analysis·2026
Same author

Sensitive RP-LC Method Enabling PTM-Specific Quality Control and MS-Compatible Characterization of Fc-Containing GLP-1 Therapeutics.

Journal of the American Society for Mass Spectrometry·2026
Same author

Rational Design, Synthesis, and Systematic Evaluation of Redox-Responsive SN-38 Prodrugs for Selective Activation in Hypoxic Tumor Microenvironments.

Pharmaceuticals (Basel, Switzerland)·2026
Same author

Longitudinal profiling of cerebrospinal fluid N-glycome dynamics in glioblastoma patients treated with apatinib.

Journal of pharmaceutical and biomedical analysis·2025
Same author

Feasibility of Rapid Regulatory Differentiation of TNF Receptor 2-Fc Fusion Protein Products from Various Manufacturers in the Chinese Market Using a Novel Mass Spectrometry-Based Multi-attribute Method (MAM).

Journal of the American Society for Mass Spectrometry·2025
Same author

Primary extraskeletal Ewing's sarcoma of the breast in a 13-year-old girl: a case report.

Frontiers in pediatrics·2025

Related Experiment Video

Updated: May 28, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

A Three-Arm, Tiered Comparability Strategy Bridging Post-Approval Process Changes for an Omalizumab Biosimilar

Chenguang Wang1,2,3,4, Chaoxin Zhou1,2,3,4, Sheng Hou1,2,3,4

  • 1State Key Laboratory of Macromolecular Drugs and Large-Scale Preparation, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China.

Pharmaceuticals (Basel, Switzerland)
|May 27, 2026
PubMed
Summary

Manufacturing changes for the omalizumab biosimilar CMAB007 were assessed using a novel tiered strategy. The study confirmed the biosimilar

Keywords:
CMAB007omalizumab biosimilarpost-approval changesthree-arm comparability strategy

More Related Videos

An Open-Source Framework for Mass Calculation of Antibody-Based Therapeutic Molecules
04:24

An Open-Source Framework for Mass Calculation of Antibody-Based Therapeutic Molecules

Published on: June 16, 2023

Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

Related Experiment Videos

Last Updated: May 28, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

An Open-Source Framework for Mass Calculation of Antibody-Based Therapeutic Molecules
04:24

An Open-Source Framework for Mass Calculation of Antibody-Based Therapeutic Molecules

Published on: June 16, 2023

Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

Area of Science:

  • Biopharmaceutical manufacturing
  • Biosimilarity assessment
  • Regulatory science

Background:

  • Post-approval manufacturing changes for biologics necessitate rigorous comparability assessments to maintain quality and clinical performance.
  • CMAB007 (Aomaishu®), an omalizumab biosimilar approved in China (2023), underwent process enhancements including media optimization and chromatography substitution, increasing production fivefold without altering the host cell line.

Purpose of the Study:

  • To evaluate the comparability of post-change CMAB007 against pre-change CMAB007 and the reference product (Xolair®) following manufacturing process enhancements.
  • To confirm the pharmacokinetic (PK) and safety equivalence of post-change CMAB007 to the reference product (Xolair®) to mitigate "biological drift" risks.

Main Methods:

  • A novel three-arm tiered strategy was employed, classifying critical quality attributes (CQAs) by risk impact with tier-specific acceptance criteria.
  • Comprehensive analytical methods assessed structural attributes, post-translational modifications, purity, impurities, activity, and Fc-mediated functions.
  • Pharmacokinetic (PK) and safety comparability was evaluated in a randomized, double-blind, two-arm study in healthy males (N=114).

Main Results:

  • Post-change CMAB007 demonstrated analytical similarity within tiered acceptance criteria for all CQAs.
  • Stability studies indicated enhanced robustness under stress conditions.
  • PK equivalence was confirmed for AUC0-inf, AUC0-t, and Cmax, with comparable immunogenicity and safety profiles between post-change CMAB007 and Xolair®.

Conclusions:

  • The study successfully pioneered a tiered three-arm comparability strategy for post-approval manufacturing changes, integrating advanced analytics, risk-based assessment, and clinical validation.
  • This approach effectively mitigates "biological drift" risks, ensuring biosimilar quality, efficacy, and safety while enabling scalable and sustainable production.